SECTION 475:25-1-17. Records of analytical laboratory activities

(a)   Each person registered or otherwise authorized to conduct analytical laboratory activites with controlled dangerous substances shall maintain records with the following information to the extent known and reasonably ascertainable by him/her for each controlled dangerous substance:

(1)   The name of the substance.

(2)   The form or forms in which the substance is received, imported, or manufactured by the registrant (e.g., powder, granulation, tablet, capsule, or solution) and the concentration of the substance in such form (e.g., C.P., U.S.P., N.D., 10-milligram tablet or 10-milligram concentration per milliliter).

(3)   The total number of the forms received, imported, or manufactured (e.g., 100 tablets, 30 1-milliliter vials, or 10 grams of powder), including the date and quantity of each receipt, importation or manufacture, and the name, address, and Federal Drug Enforcement Administration registration number, if any, of the person from whom the substance was received.

(4)   The quantity distributed or destroyed in any manner by the registrant (except quantities used in chemical analysis or other laboratory work), including the date and manner of distribution or destruction and the name, address, and Federal Drug Enforcement Administration registration number, if any, of each person to whom the substance was distributed.

(b)   Records relating to known or suspected controlled dangerous substances received as evidentiary material for analysis are not required under (a) of this Section.

(c)   Each person registered to conduct analytical laboratory activities of samples of suspected controlled dangerous substances shall maintain records containing the following information (to the extent known and reasonably ascertainable by him/her):

(1)   Laboratory identification number.

(2)   Date the sample was received.

(3)   Purported contents and actual identification.

(4)   Quantity received.

(5)   Form of sample (i.e., powder, liquid, tablets, etc.).

(6)   Description of sample.

(7)   Quantity utilized in analysis.

(8)   Disposition of sample.

(9)   Street price, if known.

(10)   Method shipment is received.

(11)   Each laboratory shall submit to the OBN a quarterly report containing at least the following information:

(A)   Actual content of drug analyzed.

(B)   Alleged content of drug analyzed.

(C)   Description of sample.

(D)   Origin of sample.

(E)   Street price, if known.

(d)   Qualitative and quantitative analysis may be conducted of samples.

(1)   Security of standards and samples, including Schedule I medical marijuana, shall be in accordance with 475:20-1-6 and 475:20-1-7, with the exception that all standards and samples must be treated as Schedules I and II.

(2)   Any unused portion of a submitted sample shall be disposed of in accordance with 475:35-1-4.

(3)   All controlled dangerous substances distributed to drug canine handler registrants and scientific research registrants shall be analyzed quantitatively, and a record of such analysis shall be maintained prior to distribution. Oklahoma State Bureau of Investigation has discretion to refuse to distribute any controlled dangerous substances. Each such registrant shall receive a copy of the quantitative analysis.

[Source: Amended at 12 Ok Reg 2843, eff 7-15-95; Amended at 36 Ok Reg 307, eff 1-4-19 (emergency); Amended at 36 Ok Reg 990, eff 7-25-19]